Hemithyroidectomy is the preferred initial operative approach for an indeterminate fine needle aspiration biopsy diagnosis

Connie G. Chiu, MD*
 Reina Yao, MD*
 Simon K. Chan, MSc†
 Scott S. Strugnell, MSc*
 Samuel Bugis, MD*
 Robert Irvine, MD*
 Donald Anderson, MD*
 Blair Walker, MD‡
 Steven J. Jones, PhD†
 Sam M. Wiseman, MD*

From *St. Paul's Hospital, Department of Surgery and University of British Columbia, the †Department of Medical Genetics, University of British Columbia and Michael Smith Genome Sciences Centre, British Columbia Cancer Research Centre, and ‡St. Paul's Hospital, Department of Pathology and Laboratory Medicine and University of British Columbia, Vancouver, BC

Accepted for publication
 May 4, 2011

Correspondence to:
 S.M. Wiseman
 St. Paul's Hospital
 Department of Surgery
 University of British Columbia
 C303-1081 Burrard St.
 Vancouver BC V6Z 1Y6
 smwiseman@providencehealth.bc.ca

DOI: 10.1503/cjs.034510

Background: Fine needle aspiration biopsy represents the critical initial diagnostic test used for evaluation of thyroid nodules. Our objectives were to determine the cytological distribution, the utility of clinicopathologic characteristics for predicting malignancy and the true proportion of cancer among individuals who presented with indeterminate cytology and had undergone thyroid surgery for suspicion of cancer.

Methods: We retrospectively reviewed 1040 consecutive primary thyroid operations carried out over an 8-year period at a tertiary care endocrine referral centre. Follicular neoplasm (FN), Hürthle cell neoplasm (HN), neoplasms suspicious for but not diagnostic of papillary carcinoma (IP) and neoplasms with cellular atypia (IA) were reviewed.

Results: In all, 380 individuals presented with cytologically indeterminate thyroid nodules. Of these, 252 (66%) patients had FN, 47 (12%) HN, 44 (12%) IP, 26 (7%) IA and 11 (4%) had mixed diagnoses. Biopsied lesions were found to be malignant on pathological evaluation in 102 (27%) patients: 49 (19%) with FN, 11 (23%) HN, 28 (64%) IP and 9 (35%) with IA. Hemithyroidectomy was adequate definitive treatment in 196 of 225 (87%) patients with FN and 39 of 42 (93%) with HN. Significant associations with a cancer diagnosis were identified for smaller tumour size in patients with FN ($p = 0.004$) and right thyroid lobe location in patients with IP ($p = 0.012$), although these factors were nonsignificant in the corrected analyses for multiple comparisons.

Conclusion: In a review of the experience at a Canadian centre, 4 operations were carried out to identify each cancer, and hemithyroidectomy was the optimal initial and definitive surgical approach for most patients.

Contexte : La biopsie par aspiration à l'aiguille fine représente un test diagnostique initial crucial pour évaluer les nodules de la thyroïde. Nos objectifs consistaient à déterminer la distribution cytologique, l'utilité des caractéristiques clinico-pathologiques pour la prédiction des cancers et la proportion réelle de cancers chez des personnes dont les résultats cytologiques étaient indéterminés et qui ont subi une chirurgie de la thyroïde pour un cancer présumé.

Méthodes : Nous avons passé en revue de façon rétrospective 1040 interventions thyroïdiennes primaires consécutives effectuées sur une période de 8 ans dans un centre de soins endocriniens tertiaires. Nous avons examiné les cas de néoplasie folliculaire (NF), de néoplasie à cellules de Hürthle (NCH), de néoplasies papillaires présumées mais non avérées (indéterminées, NPI), de même que les néoplasies à cellules atypiques (NCA).

Résultats : En tout, 380 patients ont présenté des nodules thyroïdiens indéterminés à la cytologie. Parmi eux, 252 (66 %) présentaient une NF, 47 (12 %) une NCH, 44 (12 %) une NPI, 26 (7 %) une NCA et 11 (4 %) présentaient un diagnostic mixte. Les lésions soumises à la biopsie se sont révélées malignes à l'examen anatomopathologique chez 102 patients (27 %) : 49 (19 %) présentant une NF, 11 (23 %) une NCH, 28 (64 %) une NPI et 9 (35 %) une NCA. Pour 196 patients sur 225 (87 %) présentant une NF et 39 sur 42 (93 %) présentant une NCH, l'hémithyroidectomie a été le traitement définitif adéquat. Des liens significatifs ont été établis entre, d'une part, le diagnostic de cancer et, d'autre part, la taille plus petite des nodules chez les patients présentant une NF ($p = 0,004$) et la localisation au lobe thyroïdien droit chez les patients atteints de NI ($p = 0,012$), bien que ces facteurs n'aient pas eu de portée significative aux analyses corrigées en fonction de multiples comparaisons.

Conclusion : Lors d'une revue de l'expérience accumulée dans un centre canadien, 4 interventions ont été effectuées pour reconnaître chaque cancer et l'hémithyroidectomie a été l'approche chirurgicale initiale et définitive optimale chez la plupart des patients.

Thyroid nodules are common in the general population; they are identified in about 5% of patients by palpation and 50% by ultrasound examination.¹ Fine needle aspiration biopsy (FNAB) represents the critical initial diagnostic test used for evaluation of thyroid nodules. However, in a large number of patients, the distinction between benign and malignant thyroid nodules has remained challenging for clinicians. In a review of more than 18 000 thyroid FNABs carried out at the Mayo Clinic in Rochester, Minn., FNAB had a reported sensitivity of 83%, specificity of 92% and accuracy of 95%.² Furthermore, in up to 15% of patients, the preoperative diagnosis of cancer was classified as indeterminate or suspicious for cancer.²⁻⁶ Indeterminate cytological diagnoses occur for follicular patterned thyroid lesions owing to overlapping cytomorphologic characteristics of benign and malignant lesions.^{2,3} In these patients, pathologic evaluation of the tumour specimen is required to identify additional tumour characteristics, such as the presence of capsular or vascular invasion, for an accurate diagnosis of cancer. Furthermore, the cytological evaluation of FNAB specimens of papillary carcinoma can often be challenging owing to differences in the interpretation of the required threshold of nuclear change for a cancer diagnosis.⁶ The major diagnostic criteria for papillary thyroid carcinoma (PTC) include an irregular and enlarged nucleus, eccentric micronucleoli, fine chromatin, longitudinal nuclear grooves and intranuclear pseudoinclusions. However, thyroid FNAB specimens can have some, but not all, of the features required to fulfill the cytological diagnostic criteria required for a cancer diagnosis. Such lesions may be classified as being “suspicious” or “highly suspicious” for cancer.⁴ There is also substantial inter- and intraobserver variability in cytological and pathological assessment of follicular patterned thyroid lesions.⁷

Thus, when an individual presents with a thyroid nodule and an FNAB cytological diagnosis of Hürthle cell neoplasm (HN), or an aspirate suspicious for papillary carcinoma, the current recommended approach of the American Thyroid Association is removal of either a portion of or the entire thyroid gland.⁸ Furthermore, in patients with follicular neoplasms (FN) diagnosed by FNAB, radioiodine thyroid imaging may be considered, and a diagnostic lobectomy or total thyroidectomy is recommended especially in individuals with nonfunctioning nodules.⁸ Total thyroidectomy carries a low but increased risk of permanent hypoparathyroidism and the need for lifelong calcium supplementation as well as increased risk for bilateral recurrent laryngeal nerve dysfunction and subsequent possible need for a lifelong tracheostomy compared with thyroid lobectomy. Some individuals will also require lifelong thyroid hormone replacement therapy. Surgical series have reported malignancy rates of 13%–30% for patients with FN⁹⁻¹³ and 21%–42% for those with HN.¹⁴⁻¹⁶

At our centre, a thyroid lobectomy and isthmusectomy

is performed as the initial operation for patients with an indeterminate cytological diagnosis and no clinical evidence of regional or distant metastatic disease or any other concurrent indication for total thyroidectomy (i.e., goitre, Graves disease). If gross extrathyroidal tumour extension or lymph node metastasis is found at the time of operation, a total thyroidectomy is then carried out. Intraoperative frozen section examination is not used in our management approach for FN or HN, but may be used for other cytologically indeterminate nodule types at the discretion of the operating surgeon. Consistent with the current literature, in prior reports of our experience, only about 1 in 5 patients undergoing thyroid operation for FN or HN were eventually found by histopathologic evaluation to have cancer.^{17,18} Hemithyroidectomy was considered to be adequate definitive treatment in 96% of individuals with FN and 82% with HN diagnosed preoperatively with FNAB cytology.

The present study was carried out with the aim of evaluating our current algorithm for the surgical treatment of thyroid nodules in a large prospectively collected patient cohort. Thus, our review represents a real-world experience of the treatment of thyroid nodules at a regional Canadian tertiary endocrine surgical referral centre. The aim of the study was to determine the optimal surgical approach for individuals presenting with a cytologically indeterminate thyroid nodule. We sought to determine the cytological distribution, the utility of clinicopathological characteristics for predicting malignancy and the true proportion of cancer among individuals with indeterminate cytology who undergo thyroid operation.

METHODS

We retrospectively reviewed a prospectively maintained database of 1040 consecutive primary thyroid operations performed over an 8-year period (January 2000 to July 2008) at St. Paul's Hospital in Vancouver, British Columbia. Individuals presenting with 1 or more thyroid nodules with indeterminate cytology by FNAB who had undergone thyroid lobectomy or total thyroidectomy were included in the study. Indeterminate cytology was defined as FN, HN, suspicious for but not diagnostic of papillary carcinoma (IP) and cellular atypia (IA). Cellular atypia refers to nonspecific nuclear changes on cytology that do not reflect any of the previous categories. A small number of patients presented with cytological diagnoses of FN and IP in separate FNAB specimens, and they were categorized as having “mixed diagnoses.” Each of these FNAB cytological groups carries a different probability for malignancy,⁴ and thus each group was analyzed and discussed separately. This study was conducted with ethics approval from the Providence Health Care and University of British Columbia Research Ethics Boards.

Statistical analysis

We compared clinicopathological characteristics between patients with final pathological diagnoses of benign and malignant thyroid lesions, and associations with a cancer diagnosis were determined using Mann–Whitney *U* and χ^2 tests; we considered results to be significant at $p < 0.05$.

RESULTS

During the study period, 1040 primary thyroid operations were performed at our centre. In all, 380 (37%) patients presented with an indeterminate FNAB diagnosis. Of these patients, 252 (66%) had FN, 47 (12%) HN, 44 (12%) IP, 26 (7%) IA and 11 (3%) had mixed diagnoses. The cytological distribution of the indeterminate cases is presented in Figure 1. All patients underwent surgical resection according to our management algorithm. By

Fig. 1. Cytologic distribution of 380 patients presenting with indeterminate fine needle aspiration biopsy thyroid nodules.

Fig. 2. Pathologic results for patients with indeterminate fine needle aspiration biopsy (FNAB) diagnoses of thyroid lesions.

pathological examination, cancer was identified in 49 (19%) patients with FN, 11 (23%) with HN, 9 (35%) with IA and 28 (64%) with IP (Fig. 2).

Among patients presenting with indeterminate FN cytology, 49 of 252 (19%) had tumours that were determined to be malignant on pathological evaluation. Of these, there were 11 with follicular carcinomas (FTC), 2 with Hürthle cell carcinomas (HTC), 1 with medullary carcinoma (MTC) and 35 with papillary carcinomas (PTC). Of the 35 patients with PTCs, 18 (51%) had papillary thyroid microcarcinomas (PTMC; tumour of less than 1 cm in maximal diameter) and 13 of these 18 (72%) PTMCs were associated with a benign dominant nodule (Fig. 3). Although we cannot determine whether the preoperative FNAB specimens were derived from the PTMC or an associated dominant nodule or both, we suspect that most PTMCs were incidental findings.

There were 47 patients with HN in our study cohort, 11 (23%) of whom had tumours that were found to be malignant on pathologic examination. Of these, 2 were HTCs, 9 were PTCs, and 7 of the 9 (78%) PTCs were PTMCs (Fig. 4).

Fig. 3. Pathologic diagnoses of 252 patients with follicular thyroid neoplasms undergoing surgery for suspicion of cancer.

Fig. 4. Pathologic diagnoses of 47 patients with Hürthle cell thyroid neoplasms undergoing surgery for suspicion of cancer.

Most patients (28 of 44, 64%) with an IP diagnosed by FNAB were found to have cancer. Intraoperative frozen section consultation was performed at the discretion of the operating surgeon. Intraoperative frozen section was used in 25 of 41 (61%) patients. The specimens were found to be malignant in 9 (36%) patients and benign in 5 (20%), and 11 (44%) patients had their diagnoses deferred to final pathologic evaluation. Data on the use of intraoperative frozen section were unavailable for 3 patients.

In the 26 patients presenting with a cytological IA thyroid nodule, 9 (35%) were found to have cancer on pathologic evaluation. These included 3 patients with FTCs and 6 with PTCs (of which 2 were PTMCs).

The clinicopathological characteristics of the study cohort are presented in Table 1. Individuals with preoperative diagnoses of FN, HN and IP were evaluated for patient and nodule characteristics predictive of cancer. Patients with PTMCs were included in the calculation, as the diagnosis of incidental PTMC still represents an important finding for subsequent management and follow-up. Significant associations with a cancer diagnosis were identified for smaller tumour size (mean of 2.16 cm for cancers and 3.04 cm for benign specimens, $p = 0.004$) in patients with FN and for left thyroid lobe tumour location ($p = 0.012$) for patients with IP. No other clinicopathological parameters (including age, sex, tumour laterality, size of tumour, gland

nodularity and location of tumour) reached statistical significance for the cytological groups analyzed. Furthermore, no clinicopathological factors evaluated were significant for cancer diagnosis after Benjamini–Hochberg correction. A summary of these findings is presented in Table 2.

Papillary thyroid microcarcinoma generally has a good prognosis and, unless multifocal or associated with aggressive characteristics (e.g., lymph node metastases), does not require a completion thyroid lobectomy.¹⁹ Excluding the 5 patients with multifocal PTMCs, hemithyroidectomy was considered adequate treatment in 196 of 252 (78%) of patients with FN and 39 of 47 (83%) of those with HN. Of these, 27 patients with an FN diagnosis and 5 with an HN diagnosis underwent a total thyroidectomy at their initial operation for a concurrent indication of goitre or intraoperative evidence of gross extrathyroidal tumour extension and/or nodal metastases. In the FN cohort, there were 188 benign nodules, 13 PTMCs (5 multifocal), 12 PTCs greater than 1 cm, 9 FTCs, 1 MTC and 2 HTC. In the HN cohort, there were 34 benign nodules, 6 PTMCs (1 multifocal), 1 PTC and 1 HTC. Of the patients with cancer treated at our centre, the recommendation for completion thyroidectomy and adjuvant radioactive iodine therapy was determined by tumour histology, patient characteristics, and willingness to undergo further surgery.^{8,20–22}

DISCUSSION

Fine needle aspiration biopsy is currently the critical initial test for the preoperative assessment of individuals presenting with nodular thyroid disease. Even though it has proven clinical utility in guiding the surgical treatment of thyroid tumours, follicular patterned thyroid lesions have remained a diagnostic challenge.

Numerous adjunctive tools have been investigated for their diagnostic utility in thyroid cancer management, including use of clinicopathological scores, ultrasound characteristics and molecular markers. Clinicopathological parameters have formed the foundation for commonly used thyroid cancer risk group prognostic indices and, thus, for determining utilization of postoperative adjuvant therapy. The AGES score was developed at the Mayo Clinic and uses patient age, tumour grade, tumour extent (extrathyroidal tumour extension or distant metastasis) and tumour size for categorization of individuals at low and high risk for disease recurrence and death.²³ Similarly, AMES, a risk assessment system developed at the Lahey Clinic in Burlington, Mass., uses patient age, tumour metastases, capsular or extrathyroidal tumour involvement and tumour size for disease prognostication.²⁴ In a similar fashion, investigators have attempted to identify clinicopathological characteristics that will aid in the preoperative distinction between benign and malignant thyroid nodules.^{12,25–28} Reports have shown varied results. Characteristics that have been reported to be of clinical utility in predicting malignant

Table 1. Clinicopathological characteristics of patients with indeterminate fine needle aspiration biopsy diagnoses

Characteristic	Diagnosis; no (%) [range]		
	Follicular neoplasm	Hürthle cell neoplasm	Suspicious papillary neoplasm
Age, yr			
< 45	106 (42.1)	20 (42.6)	23 (52.3)
≥ 45	146 (57.9)	27 (57.4)	21 (44.7)
Sex			
Female	210 (83.3)	37 (78.7)	33 (75.0)
Male	42 (16.7)	10 (21.3)	11 (25.0)
Side of lesion			
Left	112 (44.4)	21 (44.7)	22 (50.0)
Right	118 (46.8)	24 (51.1)	17 (38.6)
Both	2 (0.8)	0 (0)	2 (4.5)
Isthmus	7 (2.8)	1 (2.1)	2 (4.5)
Unavailable	13 (5.2)	1 (2.1)	1 (2.3)
Size of lesion, cm	2.85 [0.05–9.0]	2.10 [0.04–7.0]	2.25 [0.10–8.0]
Gland nodularity			
Uninodular	149 (59.1)	32 (68.1)	24 (54.5)
Multinodular	96 (38.1)	14 (37.8)	18 (40.9)
Unavailable	7 (2.8)	1 (2.1)	2 (4.5)
Location of lesion			
Superior	37 (14.7)	5 (10.6)	8 (18.2)
Middle	34 (13.5)	7 (14.9)	10 (22.7)
Inferior	72 (28.6)	13 (27.7)	13 (29.5)
Isthmus	7 (2.8)	2 (4.3)	0 (0)
Entire lobe	77 (30.6)	14 (29.8)	11 (25.0)
Unavailable	25 (9.9)	6 (12.8)	2 (4.5)

pathology have included male sex, large nodule size, nodule fixation, solitary nodules, hard nodules and extremes of patient age. However, other groups have not found these, or any other clinicopathological characteristics, to be useful predictors of a cancer diagnosis.^{9,29}

In the present study, smaller tumour size was significantly associated with a cancer diagnosis, although it was nonsignificant in the corrected analyses for multiple comparisons. This is in sharp contrast to prior reported surgical series. In the FN cohort, 203 patients had benign and 49 had malignant disease. Papillary thyroid microcarcinoma accounted for 18 of the 49 cases of thyroid cancer and was associated with a dominant benign nodule in 13 cases. Thus, the study findings must be interpreted in the context of these “incidental” findings of PTMC. In a study by Baloch and colleagues¹² involving 122 patients undergoing thyroid resection with a cytologically diagnosed FN between 1998 and 2000, 37 (31%) patients were classified as having malignant disease on pathological assessment. Lesions that were 3 cm or greater were significantly associated with a cancer diagnosis. In an earlier report by Tuttle and colleagues²⁸ involving 149 individuals with FN in the period 1990–1995, 103 patients underwent thyroid resection and 22 (21%) cancers were found in their cohort. Nodule size greater than 4 cm by palpation was predictive of cancer. Reasons for the opposite observations

in the present study may reflect a trend toward increased detection of smaller thyroid cancers with more widespread use of gland imaging. As a result, thyroid cancers are identified at a smaller size, including nodules that are otherwise not detectable by clinical examination.

Although patient age has been consistently used as a prognostic indicator for thyroid cancer risk stratification systems, the association between age and preoperative diagnosis of malignancy in individuals with indeterminate cytology has remained unclear. In a study by Tyler and colleagues²⁶ involving 81 patients with cytologically indeterminate thyroid nodules, cancer was identified in 9 of 10 (90%) patients with IP lesions, 8 of 43 (19%) with FN and 5 of 18 (28%) with HN. Patient age older than 50 years was significantly associated with an increased risk of cancer. In contrast, Schlinkert and colleagues²⁵ reported that younger patient age predicted malignancy in a cohort of 19 patients with FTCs among 219 patients with a diagnosis of FN who underwent thyroid surgery at the Mayo Clinic. Furthermore, in a study of 215 patients with FN in a Korean centre, cancer was identified in 102 individuals (29 PTCs, 57 FTCs, 15 HTC and 1 PMC). In this group, patient age younger than 20 years or older than 60 years was significantly associated with a final pathologic diagnosis of cancer.²⁷

Patient sex has also been extensively studied as a potential predictor of increased cancer risk in patients with

Table 2. Results of univariate analysis of clinicopathological characteristics and a cancer diagnosis

Characteristic	Follicular neoplasm				Hürthle cell neoplasm				Suspicious papillary neoplasm			
	Cancer/no.	% Cancer	<i>p</i> value	Adjusted <i>p</i> value*	Cancer/no.	% Cancer	<i>p</i> value	Adjusted <i>p</i> value*	Cancer/no.	% Cancer	<i>p</i> value	Adjusted <i>p</i> value*
Age, yr			0.84	0.89			0.16	0.36			0.14	0.36
< 45	20/106	19			2/20	10			17/23	74		
≥ 45	29/146	20			9/27	33			11/21	52		
Sex			0.72	> 0.99			0.11	0.38			> 0.99	> 0.99
Female	40/210	19			9/37	24			21/33	64		
Male	9/42	21			2/10	20			7/11	64		
Side of lesion			0.20	0.41			0.82	0.92			0.012	0.11
Left	28/112	25			4/21	19			11/22	50		
Right	18/118	15			7/24	29			15/17	88		
Both	1/2	50			0/0	NA			2/2	100		
Isthmus	1/7	14			0/1	50			0/2	0		
Size of lesion, mean cm			0.004	0.07			0.07	0.42			0.22	0.40
Benign	3.04	NA			2.15	NA			2.48	NA		
Cancer	2.16	NA			1.92	NA			2.14	NA		
Gland nodularity			0.55	0.82			0.79	0.95			0.11	0.34
Uninodular	25/149	17			7/32	22			13/24	54		
Multinodular	19/96	20			3/14	21			14/18	78		
Location of lesion			0.08	0.35			0.74	0.95			0.48	0.78
Superior	9/37	24			1/5	20			7/8	88		
Middle	13/34	38			1/7	14			7/10	70		
Inferior	12/72	17			5/13	38			8/13	62		
Isthmus	1/7	14			0/2	0			0/0	NA		
Diffuse	10/77	13			3/14	21			6/11	55		

NA = not applicable.

*Benjamini–Hochberg corrected *p* value.

indeterminate thyroid nodules. In the studies by Baloch and colleagues¹² and Tuttle and colleagues,²⁸ male sex was found to be significantly associated with increased cancer risk (47% for men v. 29% for women, $p < 0.001$ and 43% for men v. 16% for women, $p = 0.007$, respectively). However, other investigators have not found a similar association.^{9,29}

Explanations for the variations in study results may arise from differences in cytological and pathological procedures and assessments carried out at those centres as well as differences in tumour epidemiology at different study locations. Furthermore, the rarity of patients presenting with HN (47 of 380 [12%] patients in our series) and HTC (5 of 380 [1.3%] patients in our series) makes identification of important clinical diagnostic tools a challenge. Currently, there has been no single or combination of patient clinical characteristics that can reliably differentiate benign from malignant thyroid tumours.

Ultrasonographic features have also been investigated for their potential ability to identify cancer in individuals presenting with thyroid nodules.^{30,31} In a retrospective review of 849 thyroid nodules with available cytological or pathological diagnoses, ultrasonographic features that were found to be associated with cancer were taller than wide, had irregular margins, were hypoechogenic and had the presence of micro- and macrocalcification.³² However, in a report by Jeh and colleagues³³ involving 127 patients with PTC and 23 with FTC, radiological findings reported to be predictive of carcinoma were commonly found in patients with PTC but inconsistently found in those with FTC. Furthermore, other investigators have reported conflicting results.³⁴

The results of the present study should be interpreted with the recognition that the referral bias and the selection bias are inherent in most published surgical series. The number of patients that were not referred for surgical consultation or who deferred operation is not known. Thus, the true proportion of cancers among patients with indeterminate FNAB may be under- or overestimated in the present report. A recent study by Kihara and colleagues⁴⁹ reported on 445 individuals presenting with a thyroid nodule and undergoing thyroidectomy for FNAB diagnosis of benign or follicular neoplasm: 125 patients were observed for a mean of 73.8 months (range 18.3–258.0 mo) before surgical resection, and cancer was found in 8 (6.4%) patients, which compared with 37 of 320 (11.6%) patients who underwent immediate thyroid resection for diagnosis. Immediate surgery was recommended for suspicious ultrasound features, elevated serum thyroglobulin, autonomously functioning tumours or symptomatic tumours.

Recently, the molecular characterization of thyroid tumours has shown promising results for the identification of clinically applicable diagnostic markers for malignancy. In particular, in the largest thyroid cancer diagnostic marker panel study reported to date to our knowledge, 100 benign and 105 malignant thyroid tumours were

evaluated by our group for the expression of a panel of 57 different molecular markers.³⁵ The application of a panel of molecular markers to FNAB specimens would have led to 91% of patients with indeterminate FNABs receiving correct diagnoses preoperatively. In particular, many studies have focused on thyroid tumour expression of Galectin-3 and have shown its utility in distinguishing benign and malignant thyroid tumours using pathologic and FNAB specimens.^{36–42} In a recent multicentre study by Bartolazzi and colleagues,³⁹ the evaluation of Galectin-3 expression on preoperative FNAB specimens showed a sensitivity of 78%, specificity of 93% and accuracy of 88% for distinguishing benign and malignant thyroid tumours in patients presenting with cytological diagnosis of “follicular lesions” or “suspicious follicular tumours.” Preoperative testing for Galectin-3 levels in human serum^{43,44} and radio-labelled immunologic detection of Galectin-3 in murine thyroid cancer models⁴⁵ are other novel techniques for improving preoperative thyroid cancer diagnosis that are currently under investigation.

During the review of our experience with thyroid FNAB, there were large variations in the data presented in cytology reports received from different centres and even from pathologists at our own institution. In a prospective comparative study by Tsan and colleagues,⁴⁶ the implementation of a standardized cytological reporting system with defined diagnostic categories resulted in improved operating characteristics of FNAB for management of nodular thyroid disease. In particular, carcinoma was accurately identified in 100% of FNAB reports using synoptic reports compared with 67% of reports before its implementation. The Bethesda System for Reporting Thyroid Cytopathology⁴⁷ is a standardized system for thyroid FNAB reporting that has been recently developed at the National Cancer Institute using a 6-tiered cytological classification system with associated cancer risk and guidelines for management.⁴⁸

CONCLUSION

Despite its limitations, FNAB has remained the gold standard for the preoperative evaluation of individuals who present with nodular thyroid disease. In our review of the real-world experience at a single Canadian centre, cancer was identified in 49 of 252 (19%) patients with FN and 11 of 47 (23%) patients with HN. We found that by following our surgical algorithm, thyroid lobectomy was adequate definitive treatment for 196 of 252 (78%) patients with follicular patterned thyroid lesions. We also believe that our management protocol could potentially be improved with the utilization of a synoptic cytology reporting schema to ensure that individuals with diagnoses of thyroid nodular disease are treated in accordance with current clinical guidelines, such as those reported by the American Thyroid Association⁸ or the National Cancer Institute.⁴ Results from the present study suggest that the

development of other clinically relevant diagnostic tools, such as the molecular characterization of FNAB specimens, would represent an important step forward in the management of individuals who present with an indeterminate FNAB diagnosis. Until improved diagnostic tests are available, hemithyroidectomy will remain the preferred, and usually only, surgical intervention required for the treatment of individuals who present with nodular thyroid disease and an indeterminate FNAB diagnosis.

Competing interests: None declared.

Contributors: C.G. Chiu was involved in data acquisition, data analysis and interpretation, manuscript drafting and statistical expertise. R. Yao and S.S. Strugnell were involved in data acquisition, manuscript revision and administrative support. S.K. Chan and S.J. Jones were involved in data analysis and interpretation, manuscript revision and statistical expertise. S. Bugis, R. Irvine, D. Anderson and B. Walker were involved in data acquisition and manuscript revision. S.M. Wiseman was involved in study conception and design; data acquisition, analysis, and interpretation; manuscript revision; and supervision.

References

- Gharib H, Papini E. Thyroid nodules: clinical importance, assessment, and treatment. *Endocrinol Metab Clin North Am* 2007;36:707-35.
- Gharib H. Fine-needle aspiration biopsy of thyroid nodules: advantages, limitations, and effect. *Mayo Clin Proc* 1994;69:44-9.
- Ravetto C, Colombo L, Dottorini ME. Usefulness of fine-needle aspiration in the diagnosis of thyroid carcinoma: a retrospective study in 37,895 patients. *Cancer* 2000;90:357-63.
- Baloch ZW, LiVolsi VA, Asa SL, et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. *Diagn Cytopathol* 2008;36:425-37.
- Goellner JR, Gharib H, Grant CS, et al. Fine needle aspiration cytology of the thyroid, 1980 to 1986. *Acta Cytol* 1987;31:587-90.
- Caraway NP, Sneige N, Samaan NA. Diagnostic pitfalls in thyroid fine-needle aspiration: a review of 394 cases. *Diagn Cytopathol* 1993;9:345-50.
- Gerhard R, da Cunha Santos G. Inter- and intraobserver reproducibility of thyroid fine needle aspiration cytology: an analysis of discrepant cases. *Cytopathology* 2007;18:105-11.
- Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid* 2009;19:1167-214.
- McHenry CR, Thomas SR, Slusarczyk SJ, et al. Follicular or Hürthle cell neoplasm of the thyroid: Can clinical factors be used to predict carcinoma and determine extent of thyroidectomy? *Surgery* 1999;126:798-802; discussion 802-794.
- Raber W, Kaserer K, Niederle B, et al. Risk factors for malignancy of thyroid nodules initially identified as follicular neoplasia by fine-needle aspiration: results of a prospective study of one hundred twenty patients. *Thyroid* 2000;10:709-12.
- Zdon MJ, Fredland AJ, Zaret PH. Follicular neoplasms of the thyroid: Predictors of malignancy? *Am Surg* 2001;67:880-4.
- Baloch ZW, Fleisher S, LiVolsi VA, et al. Diagnosis of "follicular neoplasm": a gray zone in thyroid fine-needle aspiration cytology. *Diagn Cytopathol* 2002;26:41-4.
- Bahar G, Braslavsky D, Shpitzer T, et al. The cytological and clinical value of the thyroid "follicular lesion". *Am J Otolaryngol* 2003;24:217-20.
- Wasvary H, Czako P, Poulik J, et al. Unilateral lobectomy for Hurthle cell adenoma. *Am Surg* 1998;64:729-32; discussion 732-3.
- Chen H, Nicol TL, Zeiger MA, et al. Hürthle cell neoplasms of the thyroid: Are there factors predictive of malignancy? *Ann Surg* 1998;227:542-6.
- Dahl LD, Myssiorek D, Heller KS. Hurthle cell neoplasms of the thyroid. *Laryngoscope* 2002;112:2178-80.
- Wiseman SM, Baliski C, Irvine R, et al. Hemithyroidectomy: the optimal initial surgical approach for individuals undergoing surgery for a cytological diagnosis of follicular neoplasm. *Ann Surg Oncol* 2006;13:425-32.
- Melck A, Bugis S, Baliski C, et al. Hemithyroidectomy: the preferred initial surgical approach for management of Hurthle cell neoplasm. *Am J Surg* 2006;191:593-7.
- Orsenigo E, Beretta E, Fiacco E, et al. Management of papillary microcarcinoma of the thyroid gland. *Eur J Surg Oncol* 2004;30:1104-6.
- Azadian A, Rosen IB, Walfish PG, et al. Management considerations in Hürthle cell carcinoma. *Surgery* 1995;118:711-4, discussion 714-5.
- Bondeson L, Bondeson AG, Ljungberg O, et al. Oxyphil tumors of the thyroid: follow-up of 42 surgical cases. *Ann Surg* 1981;194:677-80.
- Gosain AK, Clark OH. Hürthle cell neoplasms. Malignant potential. *Arch Surg* 1984;119:515-9.
- Hay ID, Grant CS, Taylor WF, et al. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. *Surgery* 1987;102:1088-95.
- Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. *Surgery* 1988;104:947-53.
- Schlinkert RT, van Heerden JA, Goellner JR, et al. Factors that predict malignant thyroid lesions when fine-needle aspiration is "suspicious for follicular neoplasm". *Mayo Clin Proc* 1997;72:913-6.
- Tyler DS, Winchester DJ, Caraway NP, et al. Indeterminate fine-needle aspiration biopsy of the thyroid: identification of subgroups at high risk for invasive carcinoma. *Surgery* 1994;116:1054-60.
- Kim ES, Nam-Goong IS, Gong G, et al. Postoperative findings and risk for malignancy in thyroid nodules with cytological diagnosis of the so-called "follicular neoplasm". *Korean J Intern Med* 2003;18:94-7.
- Tuttle RM, Lemar H, Burch HB. Clinical features associated with an increased risk of thyroid malignancy in patients with follicular neoplasia by fine-needle aspiration. *Thyroid* 1998;8:377-83.
- Layfield LJ, Reichman A, Bottles K, et al. Clinical determinants for the management of thyroid nodules by fine-needle aspiration cytology. *Arch Otolaryngol Head Neck Surg* 1992;118:717-21.
- Marqusee E, Benson CB, Frates MC, et al. Usefulness of ultrasonography in the management of nodular thyroid disease. *Ann Intern Med* 2000;133:696-700.
- Gul K, Ersoy R, Dirikoc A, et al. Ultrasonographic evaluation of thyroid nodules: comparison of ultrasonographic, cytological, and histopathological findings. *Endocrine* 2009;36:464-72.

32. Moon WJ, Jung SL, Lee JH, et al. Benign and malignant thyroid nodules: US differentiation — multicenter retrospective study. *Radiology* 2008;247:762-70.
33. Jeh SK, Jung SL, Kim BS, et al. Evaluating the degree of conformity of papillary carcinoma and follicular carcinoma to the reported ultrasonographic findings of malignant thyroid tumor. *Korean J Radiol* 2007;8:192-7.
34. Rago T, Di Coscio G, Basolo F, et al. Combined clinical, thyroid ultrasound and cytological features help to predict thyroid malignancy in follicular and Hupsilonrthle cell thyroid lesions: results from a series of 505 consecutive patients. *Clin Endocrinol (Oxf)* 2007;66:13-20.
35. Wiseman SM, Melck A, Masoudi H, et al. Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis. *Ann Surg Oncol* 2008;15:2811-26.
36. Bartolazzi A, Gasbarri A, Papotti M, et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. *Lancet* 2001;357:1644-50.
37. Gasbarri A, Martegani MP, Del Prete F, et al. Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. *J Clin Oncol* 1999;17:3494-502.
38. Beesley MF, McLaren KM. Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. *Histopathology* 2002;41:236-43.
39. Bartolazzi A, Orlandi F, Saggiorato E, et al. Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. *Lancet Oncol* 2008;9:543-9.
40. Carpi A, Naccarato AG, Iervasi G, et al. Large needle aspiration biopsy and galectin-3 determination in selected thyroid nodules with indeterminate FNA-cytology. *Br J Cancer* 2006;95:204-9.
41. Saggiorato E, De Pampa R, Volante M, et al. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. *Endocr Relat Cancer* 2005;12:305-17.
42. Saggiorato E, Aversa S, Deandrei D, et al. Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas. *J Endocrinol Invest* 2004;27:311-7.
43. Saussez S, Glinier D, Chantraine G, et al. Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. *Thyroid* 2008;18:705-12.
44. Inohara H, Segawa T, Miyauchi A, et al. Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies. *Biochem Biophys Res Commun* 2008;376:605-10.
45. Bartolazzi A, D'Alessandria C, Parisella MG, et al. Thyroid cancer imaging in vivo by targeting the anti-apoptotic molecule galectin-3. *PLoS ONE* 2008;3:e3768.
46. Tsan CJ, Serpell JW, Poh YY. The impact of synoptic cytology reporting on fine-needle aspiration cytology of thyroid nodules. *ANZ J Surg* 2007;77:991-5.
47. Cibas ES, Ali SZ. The Bethesda System for Reporting Thyroid Cytopathology. *Thyroid* 2009;19:1159-65.
48. Layfield LJ, Abrams J, Cochand-Priollet B, et al. Post-thyroid FNA testing and treatment options: a synopsis of the National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. *Diagn Cytopathol* 2008;36:442-8.
49. Kihara M, Hirokawa M, Ito Y, et al. Final pathology findings after immediate or delayed surgery in patients with cytologically benign or follicular thyroid nodules. *World J Surg* 2011;35:558-62.

Canadian Journal
of Surgery

Journal canadien
de chirurgie

Change of address

We require 6 to 8 weeks' notice to ensure uninterrupted service. Please send your current mailing label, new address and the effective date of change to:

CMA Member Service Centre

1870 Alta Vista Dr.
Ottawa ON K1G 6R7

tel 888 855-2555 or
613 731-8610 x2307
fax 613 236-8864
cmamsc@cma.ca

Changement d'adresse

Il nous faut de 6 à 8 semaines d'avis afin de vous assurer une livraison ininterrompue. Veuillez faire parvenir votre étiquette d'adresse actuelle, votre nouvelle adresse et la date de la prise d'effet du changement, à l'attention du

Centre des services aux membres de l'AMC

1870, prom. Alta Vista
Ottawa ON K1G 6R7

tél 888 855-2555 ou
613 731-8610 x2307
fax 613 236-8864
cmamsc@cma.ca

ASSOCIATION
MÉDICALE
CANADIENNE

CANADIAN
MEDICAL
ASSOCIATION